Top-Rated StocksTop-RatedNASDAQ:ZVRA Zevra Therapeutics (ZVRA) Stock Price, News & Analysis $11.39 +0.39 (+3.55%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$11.32 -0.07 (-0.57%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zevra Therapeutics Stock (NASDAQ:ZVRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zevra Therapeutics alerts:Sign Up Key Stats Today's Range$10.95▼$11.4650-Day Range$9.99▼$12.6852-Week Range$8.01▼$15.03Volume730,721 shsAverage Volume975,006 shsMarket Capitalization$676.34 millionP/E Ratio12.38Dividend YieldN/APrice Target$27.14Consensus RatingBuy Company Overview Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines. Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat. Niemann-Pick disease type C is a rare, progressive genetic disorder that affects the body’s ability to transport and process cholesterol and other lipids within cells. The company was formed through the combination of Acer Therapeutics and KemPharm, completed in 2023. Zevra is headquartered in the United States and initially focuses its commercial activities on the U.S. rare-disease market, while continuing to advance additional development programs for serious and underserved conditions.AI Generated. May Contain Errors. Read More Zevra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreZVRA MarketRank™: Zevra Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 31st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialZevra Therapeutics has a consensus price target of $27.14, representing about 138.3% upside from its current price of $11.39.Amount of Analyst CoverageZevra Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zevra Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for Zevra Therapeutics are expected to grow by 16.67% in the coming year, from $0.72 to $0.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zevra Therapeutics is 12.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.73.Price to Earnings Ratio vs. SectorThe P/E ratio of Zevra Therapeutics is 12.38, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.13.Price to Book Value per Share RatioZevra Therapeutics has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zevra Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.50% of the float of Zevra Therapeutics has been sold short.Short Interest Ratio / Days to CoverZevra Therapeutics has a short interest ratio ("days to cover") of 7.16.Change versus previous monthShort interest in Zevra Therapeutics has recently increased by 24.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZevra Therapeutics does not currently pay a dividend.Dividend GrowthZevra Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.96 News SentimentZevra Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zevra Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ZVRA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zevra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zevra Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,375.00 in company stock.Percentage Held by Insiders3.70% of the stock of Zevra Therapeutics is held by insiders.Percentage Held by Institutions35.03% of the stock of Zevra Therapeutics is held by institutions.Read more about Zevra Therapeutics' insider trading history. Receive ZVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZVRA Stock News HeadlinesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Rated "Buy" by Wall Street BrokeragesOctober 8 at 2:15 AM | americanbankingnews.comZevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing FactorOctober 6, 2026 | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Reviewing Vireo Growth (OTCMKTS:VREOD) & Zevra Therapeutics (NASDAQ:ZVRA)September 30, 2026 | americanbankingnews.comZevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comZevra Therapeutics to Present at Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comZevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual SymposiumAugust 25, 2026 | quiverquant.comQZevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual SymposiumAugust 25, 2026 | globenewswire.comSee More Headlines ZVRA Stock Analysis - Frequently Asked Questions How have ZVRA shares performed this year? Zevra Therapeutics' stock was trading at $8.96 at the start of the year. Since then, ZVRA stock has increased by 27.1% and is now trading at $11.39. How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:ZVRA) released its quarterly earnings data on Wednesday, August, 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The business earned $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a trailing twelve-month return on equity of 54.54% and a net margin of 42.82%. Read the conference call transcript. When did Zevra Therapeutics IPO? Zevra Therapeutics (ZVRA) raised $66 million in an IPO on Thursday, April 16th 2015. The company issued 5,090,909 shares at $12.00-$14.00 per share. How do I buy shares of Zevra Therapeutics? Shares of ZVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Tesla (TSLA). Company Calendar Last Earnings8/05/2026Today10/09/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZVRA's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZVRA CIK1434647 Webwww.zevra.com Phone(321) 939-3416Fax319-665-2577Employees61Year Founded2006Price Target and Rating Average Price Target for Zevra Therapeutics$27.14 High Price Target$35.00 Low Price Target$20.00 Potential Upside/Downside+138.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.92 Trailing P/E Ratio12.38 Forward P/E Ratio15.82 P/E GrowthN/ANet Income$83.23 million Net Margins42.82% Pretax Margin50.92% Return on Equity54.54% Return on Assets34.15% Debt Debt-to-Equity RatioN/A Current Ratio5.17 Quick Ratio5.12 Sales & Book Value Annual Sales$106.47 million Price / Sales6.35 Cash Flow$0.98 per share Price / Cash Flow11.63 Book Value$2.75 per share Price / Book4.14Miscellaneous Outstanding Shares59,380,000Free Float57,187,000Market Cap$676.34 million OptionableOptionable Beta0.98 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ZVRA) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
